Patents Examined by Dong Jiang
  • Patent number: 7338930
    Abstract: Methods for regulating levels of nitric oxide are disclosed. The methods utilize IL-17 receptors, which may be used in conjunction with inhibitor of IL-1 and/or TNF.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: March 4, 2008
    Assignee: Immunex Corporation
    Inventor: Anthony B. Troutt
  • Patent number: 7309764
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 7, 2002
    Date of Patent: December 18, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
  • Patent number: 7309765
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 7, 2002
    Date of Patent: December 18, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
  • Patent number: 7303896
    Abstract: The present invention is directed to novel polypeptides and variants thereof of GLM-R polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Also provided are methods for detecting agents that modulate the activity of GLM-R. Also provided are methods for diagnosing and for treating disorders characterized by the over or under abundance of monocytes or macrophages.
    Type: Grant
    Filed: February 24, 2003
    Date of Patent: December 4, 2007
    Assignee: Genentech, Inc.
    Inventors: Nico P. Ghilardi, Frederic J. de Sauvage, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin Gurney, William I. Wood
  • Patent number: 7291712
    Abstract: The present invention is directed to novel polypeptides having structural homology to IL-8 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treatment and diagnosis of inflammatory diseases.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: November 6, 2007
    Assignee: Genentech, Inc.
    Inventors: Dan L. Eaton, Dorothy French, J. Christopher Grimaldi, Kenneth J. Hillan, Maria Teresa Pisabaro, Kerstin N. Schmidt, Victoria Smith, Daniel Tumas, Richard Vandlen, Colin K. Watanabe, P. Mickey Williams, William I. Wood
  • Patent number: 7285627
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 6, 2002
    Date of Patent: October 23, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
  • Patent number: 7285628
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: May 7, 2002
    Date of Patent: October 23, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Victoria Smith, William I. Wood
  • Patent number: 7282204
    Abstract: Provided are methods of treatment for tumors. In particular, methods are provided for modulating activity of a cytokine molecule and its receptor.
    Type: Grant
    Filed: March 9, 2004
    Date of Patent: October 16, 2007
    Assignee: Schering Corporation
    Inventors: Martin Oft, Terrill K. McClanahan
  • Patent number: 7273843
    Abstract: Isolated receptors for IL-17, DNA's encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response.
    Type: Grant
    Filed: December 18, 2003
    Date of Patent: September 25, 2007
    Assignee: Immunex Corporation
    Inventors: Zhengbin Yao, Melanie K. Spriggs, William C. Fanslow
  • Patent number: 7268223
    Abstract: The invention relates to soluble proteins which bind to the molecule known as IL-TIF/IL-22. The proteins can antagonize the effect of IL-TIF/IL-22 on target cells. The nucleic acid molecules encoding the proteins, and uses of the protein, are also described.
    Type: Grant
    Filed: July 31, 2001
    Date of Patent: September 11, 2007
    Assignee: Wyeth
    Inventors: Jean-Christophe Renauld, Laure Dumoutier
  • Patent number: 7268112
    Abstract: The present invention relates to methods for the treatment and repair of cartilage, including cartilage damaged by injury or cartilaginous disorders, including arthritis, comprising the administration of insulin and/or insulin variants. Optionally, the administration may be in combination with a cartilage agent (e.g., peptide growth factor, catabolism antagonist, osteo-, synovial, anti-inflammatory factor), in an extended- or sustained-release form. Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or cartilaginous disorders comprising the administration of insulin and/or insulin in combination with standard surgical techniques. Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or cartilaginous disorders comprising the administration of chondrocytes previously treated with an effective amount of insulin and/or insulin variant.
    Type: Grant
    Filed: December 17, 2003
    Date of Patent: September 11, 2007
    Assignee: Genetech, Inc.
    Inventors: Ellen H. Filvaroff, Franklin W. Okumu
  • Patent number: 7256264
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: April 8, 2003
    Date of Patent: August 14, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul Godowski, Christopher Grimaldi, Austin Gurney, William I. Wood
  • Patent number: 7250274
    Abstract: The expression vectors and methods using an E. coli expression system for the large scale production of IL-21 are described. The vectors utilize the IL-21 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Using the expression vectors, the IL-21 gene was produced in E. coli to a level of greater than 1 g/L in fed batch fermentation. Also included are OmpT deficient E. coli strains transformed with an IL-21 expression vector.
    Type: Grant
    Filed: December 12, 2003
    Date of Patent: July 31, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Chung Chan, Bruce L. Zamost, Douglas C. Covert, Hong Y. Liu, Karen S. De Jongh, Jeffrey D. Meyer, Susan D. Holderman
  • Patent number: 7247444
    Abstract: The present invention relates to the anti-cancer activity of IL-19 polypeptide molecules. IL-19 is a cytokine involved in inflammatory processes and human disease. The present invention includes Use of IL-19 for decreasing proliferation of cervical cancer cells, treating cervical cancer, amongst other uses disclosed. IL-19 polypeptides can be administered alone, or can be fused to cytotoxic moieties, and can be administered in conjunction with radiation or chemotherapeutic agents.
    Type: Grant
    Filed: April 8, 2003
    Date of Patent: July 24, 2007
    Assignee: ZymoGenetics, Inc.
    Inventors: Yasmin A. Chandrasekher, Patricia A. McKernan
  • Patent number: 7241863
    Abstract: A novel human metabotropic glutamate receptor (mGluR) protein is identified, sequenced, and cloned. The receptor may be used to screen for compounds that modulate the activity of the mGluR. The recombinant mGluR, as well as compounds that modulate mGluR activity, may be used in the diagnosis and treatment of neurological disorders and diseases.
    Type: Grant
    Filed: January 17, 2003
    Date of Patent: July 10, 2007
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Karen J. Krapcho, Thomas M. Stormann, Cynthia Levinthal, Lance G. Hammerland, Laura Storjohann
  • Patent number: 7235238
    Abstract: 2F1 polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting prostaglandin synthesis and treating inflammation.
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: June 26, 2007
    Assignee: Amgen Inc.
    Inventors: Patricia Parnet, John E. Sims
  • Patent number: 7229793
    Abstract: The present invention features a nucleic acid construct for expressing a product, e.g., a small peptide such as GLP-1. The construct includes a nucleic acid sequence encoding a signal peptide and a nucleic acid sequence which encodes the pro-region of somatostatin or a functional fragment thereof. The construct can further include a sequence encoding the small peptide or the construct can be used to express an endogenous genomic sequence encoding the small peptide. The present invention further features genetically engineered cells, and methods of using such constructs or cells.
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: June 12, 2007
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Douglas A. Treco, Michael F. Concino, Stephen J. Duguay
  • Patent number: 7220717
    Abstract: Interleukin-18 binding proteins which are capable of binding IL-18 and of modulating and/or blocking IL-18 activity are provided. Methods for the isolation and recombinant production, DNAs encoding them. DNA vectors expressing them, vectors useful for their expression in humans and other mammals, antibodies against them are also provided. Therapeutic uses of IL-18 binding proteins and further inhibitors of IL-18 are also provided according to the invention.
    Type: Grant
    Filed: February 21, 2001
    Date of Patent: May 22, 2007
    Assignee: Yeda Research and Development Company Ltd.
    Inventors: Daniela Novick, Charles Dinarello, Menachem Rubinstein, Soo Hyun Kim, Yolande Chvatchko, Christine Plater-Zyberk
  • Patent number: 7217412
    Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17 and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders.
    Type: Grant
    Filed: May 10, 2001
    Date of Patent: May 15, 2007
    Assignee: Genentech, Inc.
    Inventors: Jian Chen, Ellen Filvaroff, Audrey Goddard, Austin Gurney, Hanzhong Li, William I. Wood
  • Patent number: 7202345
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: April 24, 2002
    Date of Patent: April 10, 2007
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J. Godowski, Austin L. Gurney, William I. Wood